Bartelds and colleagues observed that RA patients who had developed antibodies to Ifx against the first anti-TNF drug had no significant differences in clinical improvement after switching (change in Disease Activity Score for 28 joints) when compared with anti-TNF-naïve patients [21]. Here, TNF is linked to rheumatoid arthritis.